EnVivo Pharmaceuticals, Inc. Announces Initiation of Phase 2 Clinical Trial Program of EVP-0962 in Alzheimer’s Disease
1/3/2013 9:54:46 AM
More...
|
EnVivo Pharmaceuticals, Inc. Presents Additional EVP-6124 Phase 2b Clinical Trial Results at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
10/31/2012 7:51:10 AM
More...
|
EnVivo Pharmaceuticals, Inc.' Drug Helps Memory in Early Study
7/18/2012 10:20:41 AM
More...
|
EnVivo Pharmaceuticals, Inc. to Present Phase 2b Clinical Data of Lead Program in Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2012
6/13/2012 10:38:51 AM
More...
|
EnVivo Pharmaceuticals, Inc. Names Christopher L. Burnley Chief Business Officer
4/19/2012 10:06:00 AM
More...
|
EnVivo Pharmaceuticals, Inc. Announces Neuropharmacology Publication, Confirms Novel Mechanism of Action of Lead Program EVP-6124
12/13/2011 7:16:19 AM
More...
|
EnVivo Pharmaceuticals, Inc. Posts Positive Phase 2b Study Results of Schizophrenia Drug
12/5/2011 6:55:33 AM
More...
|
KLAS Performance Report on Clinical Decision Support Rates First Databank Highest Among Drug Database Vendors on Key Indicators
12/5/2011 6:50:09 AM
More...
|
EnVivo Pharmaceuticals, Inc. to Highlight Clinical Stage Program at Neuroscience 2011
10/31/2011 7:54:42 AM
More...
|
EnVivo Pharmaceuticals, Inc. Announces Initiation of Gamma Secretase Modulator Clinical Program in Alzheimer’s Disease
6/27/2011 8:54:35 AM
More...
|
|